Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats
This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were rando...
        Saved in:
      
    
          | Published in | Journal of Huazhong University of Science and Technology. Medical sciences Vol. 36; no. 6; pp. 806 - 810 | 
|---|---|
| Main Author | |
| Format | Journal Article | 
| Language | English | 
| Published | 
        Wuhan
          Huazhong University of Science and Technology
    
        01.12.2016
     Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China  | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 1672-0733 1993-1352 1993-1352  | 
| DOI | 10.1007/s11596-016-1666-8 | 
Cover
| Abstract | This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH. | 
    
|---|---|
| AbstractList | This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH. This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups ( n =10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH. This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in rats and the possible mechanisms. BPH was established in the castrated rats by subcutaneous injection of testosterone propionate. Animals were randomly divided into four groups (n=10 each): model group (0.5% sodium carboxymethyl cellulose); positive control group (3 mg/kg finasteride); two diosgenin groups (50 and 100 mg/kg). The drugs were intragastricaly given in each group for consecutive 3 weeks. Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 mL olive oil per day and then treated with 0.5% sodium carboxymethylcellulose. After 3-week administration, the prostate index and serum PSA level were determined, and histopathological examination was carried out. The levels of MDA, SOD and GPx in prostates were also measured. Additionally, the expression of Bcl-2, Bax and p53 was examined using Western blotting. The results showed that the prostate index and serum PSA level were significantly decreased, and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group. Elevated activities of SOD and GPx, and reduced MDA level were also observed in diosgenin-treated rats. In addition, the expression of Bcl-2 in prostates was down-regulated, whereas that of Bax and p53 was up-regulated in diosgenin-treated rats. These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH. This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH.  | 
    
| Author | 陈静 章怀奋 熊朝梅 阮金兰 | 
    
| AuthorAffiliation | Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | 
    
| AuthorAffiliation_xml | – name: Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | 
    
| Author_xml | – sequence: 1 fullname: 陈静 章怀奋 熊朝梅 阮金兰  | 
    
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27924509$$D View this record in MEDLINE/PubMed | 
    
| BookMark | eNqNkV1rFDEUhoNU7If-AG8keCWU0XxNJrnUutqFgiJ6KSEzSaZZZ5PtJIM7_75ZZq3gRfEqgTxvzuF5z8FJiMEC8BKjtxih5l3CuJa8QphXmHNeiSfgDEtJK0xrclLuvCEVaig9BecpbRCqG07YM3BKGklYjeQZ-LkOt771OY4zXDlnuwyjgx99TL0NPsAY4Gq_s6Pf2pD1MMxwHczUWQM_lPc-wK9jTFln38HruXC7QSevYUl-0zk9B0-dHpJ9cTwvwI9Pq-9X19XNl8_rq_c3VccYylVthay5kYJKijtRt8yYlmttLJHasFYSR7kRmKKOtI0lDXZCOIsk5gzVyNELcLn8-1sHp0OvNnEaQ5mo8mb-Zfb7VllSNCFeHBT6zULvxng32ZTV1qfODoMONk5JYSGE5AKz_0FZcYxqQgv66ohO7dYatSvO9DirP64LgBegK8rSaN0DgpE69KmWPlVZVB36VKJkmn8ynT_YjiGP2g-PJsmSTGVK6O3418ljodfHcbcx9Hcl97AjbzBmRDJO7wG23L5d | 
    
| CitedBy_id | crossref_primary_10_3390_biomedicines12081636 crossref_primary_10_1016_j_sajb_2020_04_009 crossref_primary_10_1016_j_biopha_2017_03_020 crossref_primary_10_1007_s11101_020_09661_0 crossref_primary_10_1186_s43094_021_00318_z crossref_primary_10_1177_0960327119889655 crossref_primary_10_1016_j_reprotox_2024_108647 crossref_primary_10_1111_fcp_12384 crossref_primary_10_2147_RRU_S478740 crossref_primary_10_1002_tox_22876 crossref_primary_10_1016_j_bbrep_2018_03_005 crossref_primary_10_1016_j_molstruc_2018_12_009  | 
    
| Cites_doi | 10.1016/j.phytochem.2006.10.026 10.1007/s12291-012-0229-4 10.1007/s11596-014-1278-0 10.1155/2014/475876 10.1023/A:1006118628183 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J 10.1159/000315064 10.3390/ijms140714301 10.1016/S0022-5347(01)64536-1 10.1021/np500810c 10.1016/j.ejphar.2014.07.026 10.1016/j.toxlet.2013.03.002 10.1016/j.juro.2010.11.060 10.1016/j.etap.2014.02.001 10.1016/S0046-8177(96)90396-2 10.1371/journal.pone.0020164 10.1016/j.ejphar.2012.10.028 10.1111/bju.12118 10.1517/14728214.11.1.111 10.1016/S0090-4295(03)00589-2 10.1186/1423-0127-21-19 10.1126/science.281.5381.1322 10.1089/jmf.2011.1968 10.1007/s11746-998-0032-9 10.1016/S0022-5347(17)49698-4  | 
    
| ContentType | Journal Article | 
    
| Copyright | Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016 Copyright © Wanfang Data Co. Ltd. All Rights Reserved.  | 
    
| Copyright_xml | – notice: Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016 – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.  | 
    
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QO 8FD FR3 P64 2B. 4A8 92I 93N PSX TCJ  | 
    
| DOI | 10.1007/s11596-016-1666-8 | 
    
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ)  | 
    
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts  | 
    
| DatabaseTitleList | Engineering Research Database MEDLINE MEDLINE - Academic  | 
    
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database  | 
    
| DeliveryMethod | fulltext_linktorsrc | 
    
| Discipline | Medicine | 
    
| DocumentTitleAlternate | Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats | 
    
| EISSN | 1993-1352 | 
    
| EndPage | 810 | 
    
| ExternalDocumentID | tjykdxxb_e201606005 27924509 10_1007_s11596_016_1666_8 671142946  | 
    
| Genre | Journal Article | 
    
| GrantInformation_xml | – fundername: the National Nature Science Foundation of China funderid: (81173065)  | 
    
| GroupedDBID | -5E -5G -BR -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 29K 29~ 2B. 2C~ 2J2 2KG 2KM 2LR 2RA 2~H 30V 4.4 408 40D 40E 53G 5GY 5VS 6NX 8TC 8UJ 92F 92I 92L 95- 95. 95~ 96X AAAVM AABHQ AAJKR AANXM AARHV AARTL AAYIU AAYQN AAYTO ABFTV ABJNI ABJOX ABKCH ABMNI ABNWP ABQBU ABTMW ACGFS ACHXU ACKNC ACOMO ACSNA ACUDM ADHIR ADINQ ADKPE ADURQ ADYFF ADZKW AEBTG AEGNC AEJHL AEKMD AEOHA AEPYU AETLH AEXYK AFWTZ AFZKB AGAYW AGDGC AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHYZX AIIXL AJBLW AJRNO ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP ARMRJ AZFZN B-. BA0 BGNMA CAG CCEZO CHBEP CIEJG COF CQIGP CS3 CSCUP CW9 D-I DPUIP EBS EJD ESBYG FA0 FEDTE FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GQ6 GQ7 HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IXD I~X I~Z J-C JBSCW JUIAU KOV M4Y MA- N2Q NDZJH NQJWS NU0 O9- O93 O9I O9J P9S PF0 QOR QOS R-E R89 R9I RIG ROL RPX RSV S.. S16 S1Z S27 S37 S3B SAP SCL SDH SHX SMD SNE SNX SOJ SPISZ SZ9 SZN T13 TCJ TSG TT1 TUC U2A U9L UG4 VC2 W48 W91 WK8 Z7U Z82 Z8V ZOVNA ~A9 ~WA ABQSL H13 AAYXX ADHKG AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7X8 7QO 8FD FR3 P64 4A8 93N PSX  | 
    
| ID | FETCH-LOGICAL-c440t-5e8956d983931c85b4ddb6aade29ad4b92f36d8130c2b7e271f88fe09164050f3 | 
    
| IEDL.DBID | U2A | 
    
| ISSN | 1672-0733 1993-1352  | 
    
| IngestDate | Thu May 29 04:06:47 EDT 2025 Tue Oct 07 09:43:07 EDT 2025 Fri Sep 05 13:40:56 EDT 2025 Thu Apr 03 06:58:43 EDT 2025 Wed Oct 01 00:36:02 EDT 2025 Thu Apr 24 23:02:46 EDT 2025 Fri Feb 21 02:37:17 EST 2025 Wed Feb 14 10:05:33 EST 2024  | 
    
| IsPeerReviewed | false | 
    
| IsScholarly | false | 
    
| Issue | 6 | 
    
| Keywords | apoptosis diosgenin benign prostatic hyperplasia oxidative stress  | 
    
| Language | English | 
    
| LinkModel | DirectLink | 
    
| MergedId | FETCHMERGED-LOGICAL-c440t-5e8956d983931c85b4ddb6aade29ad4b92f36d8130c2b7e271f88fe09164050f3 | 
    
| Notes | diosgenin; benign prostatic hyperplasia; oxidative stress; apoptosis 42-1679/R Jing CHEN1, Huai-fen ZHANG1, Chao-mei XIONG2, Jin-lan RUAN 2( 1Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China; 2School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China) This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in rats and the possible mechanisms.BPH was established in the castrated rats by subcutaneous injection of testosterone propionate.Animals were randomly divided into four groups(n=10 each):model group(0.5% sodium carboxymethyl cellulose);positive control group(3 mg/kg finasteride);two diosgenin groups(50 and 100 mg/kg).The drugs were intragastricaly given in each group for consecutive 3 weeks.Another 10 rats with no testicles cut off served as negative controls and they were subcutaneously injected with 0.1 m L olive oil per day and then treated with 0.5% sodium carboxymethylcellulose.After 3-week administration,the prostate index and serum PSA level were determined,and histopathological examination was carried out.The levels of MDA,SOD and GPx in prostates were also measured.Additionally,the expression of Bcl-2,Bax and p53 was examined using Western blotting.The results showed that the prostate index and serum PSA level were significantly decreased,and the pathological changes of the prostate gland were greatly improved in diosgenin groups as compared with the model group.Elevated activities of SOD and GPx,and reduced MDA level were also observed in diosgenin-treated rats.In addition,the expression of Bcl-2 in prostates was down-regulated,whereas that of Bax and p53 was up-regulated in diosgenin-treated rats.These results indicated that diosgenin was effective in inhibiting testosterone propionate-induced prostate enlargement and may be a candidate agent for the treatment of BPH. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23  | 
    
| PMID | 27924509 | 
    
| PQID | 1846720523 | 
    
| PQPubID | 23479 | 
    
| PageCount | 5 | 
    
| ParticipantIDs | wanfang_journals_tjykdxxb_e201606005 proquest_miscellaneous_1888968145 proquest_miscellaneous_1846720523 pubmed_primary_27924509 crossref_primary_10_1007_s11596_016_1666_8 crossref_citationtrail_10_1007_s11596_016_1666_8 springer_journals_10_1007_s11596_016_1666_8 chongqing_primary_671142946  | 
    
| ProviderPackageCode | CITATION AAYXX  | 
    
| PublicationCentury | 2000 | 
    
| PublicationDate | 2016-12-01 | 
    
| PublicationDateYYYYMMDD | 2016-12-01 | 
    
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01  | 
    
| PublicationDecade | 2010 | 
    
| PublicationPlace | Wuhan | 
    
| PublicationPlace_xml | – name: Wuhan – name: China  | 
    
| PublicationSubtitle | Medical Sciences | 
    
| PublicationTitle | Journal of Huazhong University of Science and Technology. Medical sciences | 
    
| PublicationTitleAbbrev | J. Huazhong Univ. Sci. Technol. [Med. Sci.] | 
    
| PublicationTitleAlternate | Journal of Zuazhong University of Science and Technology: Medical Edition | 
    
| PublicationTitle_FL | Journal of Huazhong University of Science and Technology(Medical Science) | 
    
| PublicationYear | 2016 | 
    
| Publisher | Huazhong University of Science and Technology Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China  | 
    
| Publisher_xml | – name: Huazhong University of Science and Technology – name: Department of Pharmacy, the First People's Hospital of Yueyang, Yueyang 414000, China%School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China  | 
    
| References | Kaplan, Lee, Meehan (CR6) 2011; 185 Bullock, Andriole (CR8) 2006; 11 Chen, Shih, Huang (CR16) 2011; 6 Ahmad, Suhail, Mansoor (CR21) 2012; 27 Kim, Jeon, Lee (CR15) 2012; 2012 Minutoli, Altavilla, Marini (CR25) 2014; 21 Ahmed, Obaid, Zaki (CR14) 2014; 740 Sirab, Robert, Fasolo (CR11) 2013; 14 Djavan (CR2) 2003; 62 Adams, Cory (CR26) 1998; 281 Chung, Cheon, An (CR10) 2015; 78 Chen, Xiong, Song (CR17) 2012; 15 Shao, Guo, Cui (CR13) 2007; 68 van Coppenolle, Le Bourhis, Carpentier (CR18) 2000; 43 Gandaglia, Briganti, Gontero (CR3) 2013; 112 Aruoma (CR23) 1998; 75 Fleshner, Klotz (CR22) 1999; 17 Carlin, Seftel, Resnick (CR9) 1997; 158 Amaral, Xavier, Steer (CR27) 2010; 9 Roshan, Liu, Banafa (CR28) 2014; 34 Pace, Di Massimo, de Amicis (CR5) 2010; 85 Jang, Bae, Yuk (CR24) 2014; 2014 Ali, Kondreddi, Veeresh (CR19) 2013; 698 Xu, Wang, Mei (CR12) 2014; 37 Kyprianou, Tu, Jacobs (CR4) 1996; 27 Atawia, Tadros, Khalifa (CR20) 2013; 219 Berry, Coffey, Walsh (CR1) 1984; 132 Oelke, Höfner, Berges (CR7) 2002; 41 DS Kim (1666_CR15) 2012; 2012 JM Adams (1666_CR26) 1998; 281 G Pace (1666_CR5) 2010; 85 N Sirab (1666_CR11) 2013; 14 BI Carlin (1666_CR9) 1997; 158 J Chen (1666_CR17) 2012; 15 F Coppenolle van (1666_CR18) 2000; 43 NE Fleshner (1666_CR22) 1999; 17 L Minutoli (1666_CR25) 2014; 21 OI Aruoma (1666_CR23) 1998; 75 PS Chen (1666_CR16) 2011; 6 RT Atawia (1666_CR20) 2013; 219 DH Xu (1666_CR12) 2014; 37 SA Kaplan (1666_CR6) 2011; 185 JD Amaral (1666_CR27) 2010; 9 M Ahmad (1666_CR21) 2012; 27 G Gandaglia (1666_CR3) 2013; 112 MI Ali (1666_CR19) 2013; 698 N Kyprianou (1666_CR4) 1996; 27 SJ Berry (1666_CR1) 1984; 132 B Djavan (1666_CR2) 2003; 62 B Shao (1666_CR13) 2007; 68 LA Ahmed (1666_CR14) 2014; 740 M Oelke (1666_CR7) 2002; 41 S Roshan (1666_CR28) 2014; 34 KS Chung (1666_CR10) 2015; 78 H Jang (1666_CR24) 2014; 2014 TL Bullock (1666_CR8) 2006; 11 10453275 - Cancer Metastasis Rev. 1998-1999;17(4):325-30 23123055 - Eur J Pharmacol. 2013 Jan 5;698(1-3):397-403 23500659 - Toxicol Lett. 2013 May 23;219(2):160-9 21629786 - PLoS One. 2011;6(5):e20164 25062790 - Eur J Pharmacol. 2014 Oct 5;740:379-87 22719792 - Evid Based Complement Alternat Med. 2012;2012:981675 10725865 - Prostate. 2000 Apr 1;43(1):49-58 20484887 - Urol Int. 2010;85(3):328-33 24607683 - Environ Toxicol Pharmacol. 2014 Mar;37(2):679-88 12957195 - Urology. 2003 Sep;62(3 Suppl 1):6-14 24701239 - Evid Based Complement Alternat Med. 2014;2014:475876 22510101 - J Med Food. 2012 Jul;15(7):646-50 9735050 - Science. 1998 Aug 28;281(5381):1322-6 23846725 - Int J Mol Sci. 2013 Jul 10;14(7):14301-20 21334655 - J Urol. 2011 Apr;185(4):1369-73 20193641 - Discov Med. 2010 Feb;9(45):145-52 8698310 - Hum Pathol. 1996 Jul;27(7):668-75 25714330 - J Nat Prod. 2015 Apr 24;78(4):689-94 12426859 - Urologe A. 2002 Sep;41(5):425-41 16503830 - Expert Opin Emerg Drugs. 2006 Mar;11(1):111-23 24082465 - Indian J Clin Biochem. 2012 Oct;27(4):385-8 17166529 - Phytochemistry. 2007 Mar;68(5):623-30 23650937 - BJU Int. 2013 Aug;112(4):432-41 24606563 - J Biomed Sci. 2014 Mar 10;21:19 24939294 - J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):330-6 9224349 - J Urol. 1997 Aug;158(2):547 6206240 - J Urol. 1984 Sep;132(3):474-9  | 
    
| References_xml | – volume: 68 start-page: 623 issue: 5 year: 2007 end-page: 630 ident: CR13 article-title: Steroidal saponins from Smilax china and their anti-inflammatory activities publication-title: Phytochemistry doi: 10.1016/j.phytochem.2006.10.026 – volume: 27 start-page: 385 issue: 4 year: 2012 end-page: 388 ident: CR21 article-title: Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls publication-title: Indian J Clin Biochem doi: 10.1007/s12291-012-0229-4 – volume: 34 start-page: 330 issue: 3 year: 2014 end-page: 336 ident: CR28 article-title: Fucoidan induces apoptosis of HepG2 cells by down-regulating p-Stat3 publication-title: J Huazhong Univ Sci Technol [Med Sci] doi: 10.1007/s11596-014-1278-0 – volume: 2014 start-page: 475876 year: 2014 ident: CR24 article-title: Seoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasia publication-title: Evid Based Complement Alternat Med doi: 10.1155/2014/475876 – volume: 17 start-page: 325 issue: 4 year: 1999 end-page: 330 ident: CR22 article-title: Diet, androgens, oxidative stress and prostate cancer susceptibility publication-title: Cancer Metastasis Rev doi: 10.1023/A:1006118628183 – volume: 43 start-page: 49 issue: 1 year: 2000 end-page: 58 ident: CR18 article-title: Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride publication-title: Prostate doi: 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J – volume: 85 start-page: 328 issue: 3 year: 2010 end-page: 333 ident: CR5 article-title: Oxidative stress in benign prostatic hyperplasia and prostate cancer publication-title: Urol Int doi: 10.1159/000315064 – volume: 14 start-page: 14301 issue: 7 year: 2013 end-page: 14320 ident: CR11 article-title: Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells publication-title: Int J Mol Sci doi: 10.3390/ijms140714301 – volume: 158 start-page: 547 issue: 2 year: 1997 ident: CR9 article-title: Finasteride induced gynecomastia publication-title: J Urol doi: 10.1016/S0022-5347(01)64536-1 – volume: 78 start-page: 689 issue: 4 year: 2015 end-page: 694 ident: CR10 article-title: Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflamematory and apoptotic proteins publication-title: J Nat Prod doi: 10.1021/np500810c – volume: 740 start-page: 379 year: 2014 end-page: 387 ident: CR14 article-title: Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotalin-induced pulmonary hypertension in rats publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2014.07.026 – volume: 219 start-page: 160 issue: 2 year: 2013 end-page: 169 ident: CR20 article-title: Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2013.03.002 – volume: 9 start-page: 145 issue: 45 year: 2010 end-page: 152 ident: CR27 article-title: The role of p53 in apoptosis publication-title: Discov Med – volume: 185 start-page: 1369 issue: 4 year: 2011 end-page: 1373 ident: CR6 article-title: Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial publication-title: J Urol doi: 10.1016/j.juro.2010.11.060 – volume: 37 start-page: 679 issue: 2 year: 2014 end-page: 688 ident: CR12 article-title: Protective effects of seahorse extracts in a rat castration and testosterone-induced benign prostatic hyperplasia model and mouse oligospermatism model publication-title: Environ Toxicol Pharmacol doi: 10.1016/j.etap.2014.02.001 – volume: 27 start-page: 668 issue: 7 year: 1996 end-page: 675 ident: CR4 article-title: Apoptotic versus proliferative activities in human benign prostatic hyperplasia publication-title: Hum Pathol doi: 10.1016/S0046-8177(96)90396-2 – volume: 6 start-page: e20164 issue: 5 year: 2011 ident: CR16 article-title: Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression publication-title: PLoS One doi: 10.1371/journal.pone.0020164 – volume: 698 start-page: 397 issue: 1-3 year: 2013 end-page: 403 ident: CR19 article-title: Protective effect of 2-hydroxy-4-methoxy benzoic acid on testosterone induced benign prostatic hyperplasia in Wister rats publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2012.10.028 – volume: 112 start-page: 432 issue: 4 year: 2013 end-page: 441 ident: CR3 article-title: The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH) publication-title: BJU Int doi: 10.1111/bju.12118 – volume: 132 start-page: 474 issue: 3 year: 1984 end-page: 479 ident: CR1 article-title: The development of human benign prostatic hyperplasia with age publication-title: J Urol – volume: 11 start-page: 111 issue: 1 year: 2006 end-page: 123 ident: CR8 article-title: Emerging drug therapies for benign prostatic hyperplasia publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.11.1.111 – volume: 62 start-page: 6 year: 2003 end-page: 14 ident: CR2 article-title: Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient’s quality of life publication-title: Urology doi: 10.1016/S0090-4295(03)00589-2 – volume: 2012 start-page: 981675 year: 2012 ident: CR15 article-title: Diosgenin induces apoptosis in HepG2 cells through generation of reactive oxygen species and mitochondrial pathway publication-title: Evid Based Complement Alternat Med – volume: 41 start-page: 425 issue: 5 year: 2002 end-page: 441 ident: CR7 article-title: Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers publication-title: Basic principles and clinical results. Urologe A – volume: 21 start-page: 19 year: 2014 ident: CR25 article-title: Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene publication-title: J Biomed Sci doi: 10.1186/1423-0127-21-19 – volume: 281 start-page: 1322 issue: 5381 year: 1998 end-page: 1326 ident: CR26 article-title: The Bcl-2 protein family: arbiters of cell survival publication-title: Science doi: 10.1126/science.281.5381.1322 – volume: 15 start-page: 646 issue: 7 year: 2012 end-page: 650 ident: CR17 article-title: Fraction of macroporous resin from Smilax china L. inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats publication-title: J Med Food doi: 10.1089/jmf.2011.1968 – volume: 75 start-page: 199 issue: 2 year: 1998 end-page: 212 ident: CR23 article-title: Free radicals, oxidative stress, and antioxidants in human health and disease publication-title: J Am Oil Chem Soc doi: 10.1007/s11746-998-0032-9 – volume: 27 start-page: 668 issue: 7 year: 1996 ident: 1666_CR4 publication-title: Hum Pathol doi: 10.1016/S0046-8177(96)90396-2 – volume: 740 start-page: 379 year: 2014 ident: 1666_CR14 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2014.07.026 – volume: 21 start-page: 19 year: 2014 ident: 1666_CR25 publication-title: J Biomed Sci doi: 10.1186/1423-0127-21-19 – volume: 43 start-page: 49 issue: 1 year: 2000 ident: 1666_CR18 publication-title: Prostate doi: 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J – volume: 9 start-page: 145 issue: 45 year: 2010 ident: 1666_CR27 publication-title: Discov Med – volume: 158 start-page: 547 issue: 2 year: 1997 ident: 1666_CR9 publication-title: J Urol doi: 10.1016/S0022-5347(01)64536-1 – volume: 85 start-page: 328 issue: 3 year: 2010 ident: 1666_CR5 publication-title: Urol Int doi: 10.1159/000315064 – volume: 281 start-page: 1322 issue: 5381 year: 1998 ident: 1666_CR26 publication-title: Science doi: 10.1126/science.281.5381.1322 – volume: 17 start-page: 325 issue: 4 year: 1999 ident: 1666_CR22 publication-title: Cancer Metastasis Rev doi: 10.1023/A:1006118628183 – volume: 75 start-page: 199 issue: 2 year: 1998 ident: 1666_CR23 publication-title: J Am Oil Chem Soc doi: 10.1007/s11746-998-0032-9 – volume: 698 start-page: 397 issue: 1-3 year: 2013 ident: 1666_CR19 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2012.10.028 – volume: 132 start-page: 474 issue: 3 year: 1984 ident: 1666_CR1 publication-title: J Urol doi: 10.1016/S0022-5347(17)49698-4 – volume: 185 start-page: 1369 issue: 4 year: 2011 ident: 1666_CR6 publication-title: J Urol doi: 10.1016/j.juro.2010.11.060 – volume: 34 start-page: 330 issue: 3 year: 2014 ident: 1666_CR28 publication-title: J Huazhong Univ Sci Technol [Med Sci] doi: 10.1007/s11596-014-1278-0 – volume: 41 start-page: 425 issue: 5 year: 2002 ident: 1666_CR7 publication-title: Basic principles and clinical results. Urologe A – volume: 11 start-page: 111 issue: 1 year: 2006 ident: 1666_CR8 publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.11.1.111 – volume: 112 start-page: 432 issue: 4 year: 2013 ident: 1666_CR3 publication-title: BJU Int doi: 10.1111/bju.12118 – volume: 6 start-page: e20164 issue: 5 year: 2011 ident: 1666_CR16 publication-title: PLoS One doi: 10.1371/journal.pone.0020164 – volume: 2014 start-page: 475876 year: 2014 ident: 1666_CR24 publication-title: Evid Based Complement Alternat Med doi: 10.1155/2014/475876 – volume: 14 start-page: 14301 issue: 7 year: 2013 ident: 1666_CR11 publication-title: Int J Mol Sci doi: 10.3390/ijms140714301 – volume: 27 start-page: 385 issue: 4 year: 2012 ident: 1666_CR21 publication-title: Indian J Clin Biochem doi: 10.1007/s12291-012-0229-4 – volume: 68 start-page: 623 issue: 5 year: 2007 ident: 1666_CR13 publication-title: Phytochemistry doi: 10.1016/j.phytochem.2006.10.026 – volume: 78 start-page: 689 issue: 4 year: 2015 ident: 1666_CR10 publication-title: J Nat Prod doi: 10.1021/np500810c – volume: 219 start-page: 160 issue: 2 year: 2013 ident: 1666_CR20 publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2013.03.002 – volume: 2012 start-page: 981675 year: 2012 ident: 1666_CR15 publication-title: Evid Based Complement Alternat Med – volume: 15 start-page: 646 issue: 7 year: 2012 ident: 1666_CR17 publication-title: J Med Food doi: 10.1089/jmf.2011.1968 – volume: 37 start-page: 679 issue: 2 year: 2014 ident: 1666_CR12 publication-title: Environ Toxicol Pharmacol doi: 10.1016/j.etap.2014.02.001 – volume: 62 start-page: 6 year: 2003 ident: 1666_CR2 publication-title: Urology doi: 10.1016/S0090-4295(03)00589-2 – reference: 23123055 - Eur J Pharmacol. 2013 Jan 5;698(1-3):397-403 – reference: 20193641 - Discov Med. 2010 Feb;9(45):145-52 – reference: 23650937 - BJU Int. 2013 Aug;112(4):432-41 – reference: 20484887 - Urol Int. 2010;85(3):328-33 – reference: 10725865 - Prostate. 2000 Apr 1;43(1):49-58 – reference: 16503830 - Expert Opin Emerg Drugs. 2006 Mar;11(1):111-23 – reference: 24606563 - J Biomed Sci. 2014 Mar 10;21:19 – reference: 21629786 - PLoS One. 2011;6(5):e20164 – reference: 9224349 - J Urol. 1997 Aug;158(2):547 – reference: 25714330 - J Nat Prod. 2015 Apr 24;78(4):689-94 – reference: 12957195 - Urology. 2003 Sep;62(3 Suppl 1):6-14 – reference: 17166529 - Phytochemistry. 2007 Mar;68(5):623-30 – reference: 9735050 - Science. 1998 Aug 28;281(5381):1322-6 – reference: 25062790 - Eur J Pharmacol. 2014 Oct 5;740:379-87 – reference: 12426859 - Urologe A. 2002 Sep;41(5):425-41 – reference: 24082465 - Indian J Clin Biochem. 2012 Oct;27(4):385-8 – reference: 6206240 - J Urol. 1984 Sep;132(3):474-9 – reference: 21334655 - J Urol. 2011 Apr;185(4):1369-73 – reference: 24607683 - Environ Toxicol Pharmacol. 2014 Mar;37(2):679-88 – reference: 22719792 - Evid Based Complement Alternat Med. 2012;2012:981675 – reference: 24939294 - J Huazhong Univ Sci Technolog Med Sci. 2014 Jun;34(3):330-6 – reference: 23846725 - Int J Mol Sci. 2013 Jul 10;14(7):14301-20 – reference: 10453275 - Cancer Metastasis Rev. 1998-1999;17(4):325-30 – reference: 24701239 - Evid Based Complement Alternat Med. 2014;2014:475876 – reference: 8698310 - Hum Pathol. 1996 Jul;27(7):668-75 – reference: 22510101 - J Med Food. 2012 Jul;15(7):646-50 – reference: 23500659 - Toxicol Lett. 2013 May 23;219(2):160-9  | 
    
| SSID | ssj0057624 | 
    
| Score | 1.7441967 | 
    
| Snippet | This study investigated the effect of diosgenin,a natural sapogenin possessing various pharmacological activities,on benign prostatic hyperplasia(BPH) in... This study investigated the effect of diosgenin, a natural sapogenin possessing various pharmacological activities, on benign prostatic hyperplasia (BPH) in...  | 
    
| SourceID | wanfang proquest pubmed crossref springer chongqing  | 
    
| SourceType | Aggregation Database Index Database Enrichment Source Publisher  | 
    
| StartPage | 806 | 
    
| SubjectTerms | Animals Apoptosis bcl-2-Associated X Protein - metabolism Diosgenin - pharmacology Diosgenin - therapeutic use Glutathione Peroxidase - metabolism Male Malondialdehyde - metabolism Medicine Medicine & Public Health Oxidative Stress Prostate - drug effects Prostate - metabolism Prostate-Specific Antigen - blood Prostatic Hyperplasia - drug therapy Proto-Oncogene Proteins c-bcl-2 - metabolism Rats Rats, Sprague-Dawley Superoxide Dismutase - metabolism Tumor Suppressor Protein p53 - metabolism  | 
    
| Title | Inhibitory Effect of Diosgenin on Experimentally Induced Benign Prostatic Hyperplasia in Rats | 
    
| URI | http://lib.cqvip.com/qk/85740A/201606/671142946.html https://link.springer.com/article/10.1007/s11596-016-1666-8 https://www.ncbi.nlm.nih.gov/pubmed/27924509 https://www.proquest.com/docview/1846720523 https://www.proquest.com/docview/1888968145 https://d.wanfangdata.com.cn/periodical/tjykdxxb-e201606005  | 
    
| Volume | 36 | 
    
| hasFullText | 1 | 
    
| inHoldings | 1 | 
    
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1993-1352 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057624 issn: 1672-0733 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1993-1352 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057624 issn: 1672-0733 databaseCode: U2A dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature  | 
    
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglRAXVN6hUBmpJ1CkxLEd57hCLQVUTqxUDsiKX7sLlbM0W6n9953JY3cRaCXOmdiRZ-z5JjPzmZBjUVhw-8amhgueclEXcA6KkJZVWZSOWYi3sRv5_Ks8m_LPF-Ji6ONux2r3MSXZndSbZjfwvBj9yhRTXam6T_YFsnmBEU_ZZDx-AT_3N9nKEssqi2JMZf5rCCRUmDdx9hum-9Mx_YU2tzKlXX9PDHWcbbmi0wPyaMCQdNIr_TG55-MT8uB8yJI_JT8-xfnCLDB9Tvt6DdoE6hZNC9ayiLSJdJvY__KWQmAOKnbUwPNZpEtsBUEqVzqHMPVq2bVaghAFc2mfkenpybcPZ-lwjUJqOc9WqfAKgiBXARQqcquE4c4ZWdfOs6p23FQsFNIpcGaWmdKzMg9KBQ9AQgKay0LxnOzFJvqXhHJZK1fbLHdZ4AFvA8wUxHu2BtyC0CEhh-v11MueLkPLEvt1Ky4Tko0rrO3AQI4XYVzqDXcyKkhj1RkqSKuEvFu_Mo63Q_jtqDYNmwQzH3X0zXWrc0RZDP-A75JRqpIq5yIhL3qdr6dElkUO0Coh70cj0MNeb3d9z_FgJxvh1c_bX-7mxmjPkNsP4KZ49V-DHpKHrDNgrKh5TfZWV9f-DeCilTki-5OP37-cHHX74Q7ZzgNX | 
    
| linkProvider | Springer Nature | 
    
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkYAL4tmmpWCknkCR8nAc51ghqi10e-pKvSArtuPdhcpZmq3U_vvO5LG7iGolzpnYkWfs-SYz8xngKEsNun1tQs0zHvKsTPEczFyYF3ma28RgvE3dyONzMZrw75fZZd_H3QzV7kNKsj2p181u6Hkp-hUhpbpC-RieEH8VEeZPkuPh-EX83N1kK3Iqq0zTIZX50BBEqDCr_fQPTve3Y_oHbW5kStv-Hu9KP91wRScv4UWPIdlxp_RX8Kjyr-HpuM-Sv4Gfp34213NKn7OuXoPVjtl53aC1zD2rPdsk9r-6YxiYo4ot0_h86tmCWkGIypXNMEy9XrStlijE0FyatzA5-XbxdRT21yiEhvNoGWaVxCDIFgiF0tjITHNrtShLWyVFabkuEpcKK9GZmUTnVZLHTkpXIZAQiOYil76DHV_7ag8YF6W0pYliGznu6DbASGK8Z0rELQQdAjhYradadHQZSuTUr1twEUA0rLAyPQM5XYRxpdbcyaQgRVVnpCAlA_i8emUYb4vwp0FtCjcJZT5KX9U3jYoJZSX0B3ybjJSFkDHPAtjtdL6aklgWOUKrAL4MRqD6vd5s-56j3k7Wwstfd7_t7a1WVULcfgg3s_3_GvQjPBtdjM_U2en5jwN4nrTGTNU172FneX1THSJGWuoP7Z64BwF3BK8 | 
    
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSBMviPEzGwMj7QkULXFsx3mc2KoN2MQDlfaCrDi228LkdEsmbf89d03SFoEq8RzHjnxn33e5u-8IORBZBWbfVLHhgsdclBncg8LHeZFnuWUV-NtYjXx-IU_H_POluOz7nDZDtvsQkuxqGpClKbSHc-sPV4VvYIXRE5Yxhr1i9ZA84siTAAo9ZkfDVQxYuutqK3NMscyyIaz5rymQXGFah8k1LP2nkfoLea5FTRe1PsGXYbJmlkZPyZMeT9KjTgF2yAMXnpHt8z5i_pz8OAvTmZlhKJ12uRu09tTO6gY0ZxZoHeg6yf_VPQUnHcRtqYHnk0DnWBaCtK50Ci7rzXxRdgmDKKhO84KMRyffP53GfUuFuOI8aWPhFDhEtgBYlKWVEoZba2RZWseK0nJTMJ9Jq8CwVczkjuWpV8o7ABUSkF3is5dkK9TBvSaUy1LZskpSm3jusTNgosD3q0rAMAgjIrK33E8976gztMyxdrfgMiLJsMO66tnIsSnGlV7xKKOANGagoYC0isiH5SvDfBsGvx_EpuHAYBSkDK6-bXSKiIvh3_BNY5QqpEq5iMirTubLJZFxkQPMisjHQQl0f-6bTd9z0OvJanD78_6Xvbsz2jHk-QPoKXb_a9J3ZPvb8Uh_Pbv4skces4UuY6LNG7LV3ty6fYBLrXm7OBK_AfHSCOs | 
    
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+effect+of+diosgenin+on+experimentally+induced+benign+prostatic+hyperplasia+in+rats&rft.jtitle=Journal+of+Huazhong+University+of+Science+and+Technology.+Medical+sciences&rft.au=Chen%2C+Jing&rft.au=Zhang%2C+Huai-fen&rft.au=Xiong%2C+Chao-mei&rft.au=Ruan%2C+Jin-lan&rft.date=2016-12-01&rft.issn=1672-0733&rft.eissn=1993-1352&rft.volume=36&rft.issue=6&rft.spage=806&rft.epage=810&rft_id=info:doi/10.1007%2Fs11596-016-1666-8&rft.externalDBID=NO_FULL_TEXT | 
    
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85740A%2F85740A.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Ftjykdxxb-e%2Ftjykdxxb-e.jpg  |